Pretreatment knowledge of chemosensitivity and side-effects of chemotherapy for colorectal cancer (CRC) patients are likely to ensure the best chemotherapeutic outcome. The aim of this study was to identify additional predictive factors of chemosensitivity to the key CRC treatment drug 5-fluorouracil (5-FU). Surgically obtained specimens from 106 patients treated for CRC were immunohistochemically assessed to investigate the correlation between the protein expression of the 5-FU metabolic enzymes orotate phosphoribosyltransferase (OPRT), thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD), and clinicopathological characteristics as well as the correlation between the protein expression and outcomes of 5-FU-based chemotherapy. A correlation was detected between the high expression of the 5-FU metabolic enzyme OPRT and negative lymph node metastasis (P=0.0496), as well as between DPD and advanced Tumor-Node-Metastasis (TNM) grade cases (IIIA-IVB) and positive lymph node metastases (P=0.0414, respectively). In all 106 patients and in 79 patients undergoing 5-FU-based chemotherapy, survival was improved in those patients with a positive OPRT expression (P=0.0144 and 0.0167, respectively). OPRT expression was higher in the 79 patients with no recurrence (P=0.0179) as well as in patients treated with R0 surgery and 5-FU-based chemotherapy without side-effects (P= 0.0126). Disease-free survival (DFS) rate was higher in patients without side-effects, and in patients with a positive OPRT expression without side-effects (P=0.0021 and 0.0031, respectively). Findings of this study demonstrated that OPRT expression positively correlated with fewer side-effects of 5-FU-based chemotherapy and longer patient survival.
Introduction
Colorectal cancer (CRC) is one of the most common and life-threatening types of cancer worldwide (1) . Through the development of multidisciplinary care and advances in surgical procedures and techniques over the past decade (2) , additional treatment strategies and chemotherapeutic regimens have been found to be beneficial even for advanced-stage cancer. Improved combinations of 5-fluorouracil (5-FU)/folinic acid with irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) have progressively increased tumor response up to 73%, while the median survival time (MST) of patients with unresectable tumor has increased to 20 months (3).
Over the past several years, the selection of chemotherapeutic regimens has expanded greatly and satisfactorily due to the development of molecular-targeted therapy (4) . In this context, 5-FU has become crucial in chemotherapeutic regimens for gastrointestinal cancer (5) . 5-FU metabolic enzymes, orotate phosphoribosyltransferase (OPRT), thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) are considered important predictive factors of the chemotherapeutic effect even in recently developed regimens (6) (7) (8) . In the present study, the expression of these 5-FU metabolic enzymes and their correlation with beneficial outcomes, such as patient prognosis, as well as unfavorable outcomes, such as potential side-effects, were evaluated.
Materials and methods
Patients. Surgically obtained specimens from 106 CRC patients who were operated on between January, 2004 and April, 2008 in the Department of Surgical Oncology (Gifu University School of Medicine, Gifu, Japan), were investigated in this study (Table I) Table II , 79 patients were treated with 5-FU-based chemotherapies, such as FOLFOX alone (n=22) or in combination with bevacizumab (n=3), 5-FU with leucovorin (n=16), as well as uracil/tegafur (UFT) alone (n=17) or in combination with leucovorin (n=17). Side-effects of chemotherapy were classified according to the Common Terminology Criteria for Adverse Events (CTCAE v4.03). In this study, any event over grade 1 was regarded as a chemotherapy-induced side-effect. Experiments were planned carefully in accordance with the Ethical Standards of the Helsinki Declaration of 1975. In addition, the Institutional Research Ethics Board of the Gifu University (Gifu, Japan) approved this retrospective study.
Immunohistochemical staining. Formalin-fixed, paraffinembedded blocks of CRC specimens were obtained from the Division of Clinical Pathology of our institution, the Gifu University Graduate School of Medicine (Gifu, Japan). Details of the immunohistochemical staining techniques used have been previously described (9) (10) (11) . Antigen retrieval was performed by autoclaving the sections in 0.01 M citrate buffer for TS and in ethylenediaminetetraacetic acid (EDTA) (pH 8.0) buffer for DPD for 60 sec at 120˚C (DakoCytomation, Glostrup, Denmark). Endogenous peroxidase was quenched with 0.3% hydrogen peroxide methanol for 20 min. The immunoperoxidase procedure [avidin-biotin-complex (ABC) method, VECTASTAIN ® Elite ABC kit; Vector Laboratories, Inc., Burlingame, CA, USA] was used. Primary antibodies were incubated overnight at 4˚C. 3,3'-Diaminobenzidine tetrahydrochloride (DAB) (Dojin, Osaka, Japan) was applied for 2-3 min, and slides were counterstained with hematoxylin. Protein expression was evaluated by counting the number of cells with positive cytoplasmic staining among 200 tumor cells/field in 10 fields and scored as: staining percentage (SP) <10%, 0 points; SP≥10 and <30%, 1 point; SP≥30 and 50%, 2 points and SP≥50%, 3 points ( Fig. 1 ), as previously reported (7, 12) . The average score of each category was calculated. Two co-authors (HT and KN) blinded to any prior knowledge of the clinico-pathological parameters evaluated the stained sections, and an expression index for each factor was calculated by averaging the percentage of positive cytoplasmic staining (7) .
Statistical analysis. Data were presented as the mean ± SD and were evaluated for statistical significance using the 
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recurrence. Expression of the three 5-FU metabolic enzymes was also evaluated from the viewpoint of patient prognosis (Fig. 2) . In all the cases, the OS rate was higher in patients with a positive OPRT expression (75.5%) vs. a negative OPRT expression (24.5%) (MST, not reached vs. 42.3 months, P= 0.0144).
In the 79 patients receiving 5-FU-based chemotherapy, the OS rate was also higher in patients with a positive OPRT expression (75.9%) vs. a negative OPRT expression (24.1%) (MST, not reached vs. 39.5 months, P= 0.0167). Furthermore, in these 79 patients, OPRT expression was markedly higher in the patients with no recurrence vs. those with early recurrence (recurrence within 1 year with any metastasis at surgery) (1.759±0.951 vs. 1.143±1.049, P= 0.0179) ( Fig. 3) . No statistically significant differences were detected in the expression of DPD and TS (data not shown).
Correlations between enzyme expression and side-effects, and between patient prognosis and side-effects.
Side-effects were detected in 43/79 (54.4%) patients receiving 5-FU-based chemotherapy. Of the 49 patients undergoing R0 surgery, side-effects occurred in 20 (40.8%). The expression level of OPRT was markedly lower in patients positive for side-effects compared with patients negative for side-effects (1.05±0.86 vs. 1.86±1.11, P=0.0126) (Table IV) . The correlation between side-effects and patient prognosis was compared in patients with no preoperative metastasis (n=49). DFS was markedly better in patients without side-effects (59.2%, not reached) compared with those with side-effects (40.8%, 13.6 months) (P= 0.0021) (Fig. 4A ). Furthermore, in patients with positive OPRT expression and with no side-effects, DFS (not reached) was markedly improved compared with patients (not reached vs. 13.2 months, P= 0.0031; not reached vs. 8.2 months, P= 0.0001) (Fig. 4B) . No statistically significant differences were detected in TS or DPD expression with regard to prognosis (data not shown).
Discussion
Combination chemotherapies with 5-FU/folinic acid have progressively improved tumor response and MST. According to the National Cancer Comprehensive Network (NCCN) Guidelines ® (Colon cancer, version 3, 2009; Rectal cancer, version 2, 2012), 5-FU is a key chemotherapeutic agent for CRC. However, the importance of 5-FU-related metabolic enzymes in the evaluation of patient outcome with respect to CRC patient prognosis remains controversial. In the present study, due to the fact that adjuvant chemotherapy for stage IIB/C CRC, considered a high-risk group for recurrence (13) , is recommended but not required, patients were assessed according to TNM classification as IIIA-IVB patients with and 0-IIC patients without chemotherapy. Cancer progression was observed to have a significant correlation with both OPRT and DPD expression, although not with TS expression. Furthermore, Table IV . Correlation between enzyme expression and side-effects.
Patients with no metastasis prior to surgery Patients receiving 5-FU-based chemotherapy (n=79) (receiving 5-FU-based chemotherapy) (n=49) OPRT expression, but not TS and DPD expression, was identified as a predictor of patient prognosis and occurrence of side-effects caused by 5-FU-based chemotherapy. Of these three metabolic factors, the expression of OPRT protein was more easily detected in primary CRC with progressive depth of invasion or lymph node metastasis in gastrointestinal cancer (12, 14, 15) , even in the early stages of carcinogenesis (16, 17) . Therefore, OPRT might be valuable as a predictive indicator of chemotherapeutic effects. The significance of TS or DPD expression has been controversial over the past decade (18, 19) , and a recent study estimated TS to be critical for patient prognosis in pancreatic and breast cancers (7, 20) . Furthermore, although DPD expression was associated with the progression of carcinogenesis in lymphatic/venous invasion in esophageal cancer or CRC (14, 17) , DPD itself has yet to be identified as a predictor of the effect of 5-FU-based chemotherapy.
OPRT is known to be one of the metabolic enzymes necessary for the conversion of 5-FU to its active nucleotide type, and several previous studies evaluated OPRT expression in mRNA (6, 21) . The present study evaluated the expression of OPRT and has shown a correlation between OPRT protein expression and patient prognosis. Our results were based on the response to 5-FU as a cell-killing agent, and with regard to side-effects. When severe side-effects occur, chemotherapy should be discontinued, despite its effectiveness in inhibiting cancer growth. Previous studies of OPRT mRNA expression have demonstrated a correlation between the expression of this metabolic enzyme and the occurrence of side-effects in patients treated with 5-FU-based chemotherapy (22) (23) (24) . According to an experimental study evaluating these factors (25) , protein expression was more important as compared with mRNA expression in demonstrating enzyme activity. Thus, the present study suggests OPRT protein expression to be a predictor of the occurrence of side-effects.
Both 2-fluoro-β-alanine (F-β-alanine) and 5-fluoro-deoxyuridine diphosphate (FdUMP), metabolized by DPD and OPRT, respectively, were reported to induce neurological and gastrointestinal toxicity, as well as hematotoxicity (26) (27) (28) . It is reasonable to expect that a decrease in the dose of F-β-alanine, which induces neurological toxicity, results in a reduction of side-effects. However, FdUMP has two opposing effects: first, as an anticancer agent, and second, as a factor in gastrointestinal toxicity and hematotoxicity, although an anticancer drug with few side-effects as well as increased carcinostatic effects is ideal for cancer patients. Consequently, future studies verifying the mechanism of FdUMP and its interactions with other factors in humans are required.
In conclusion, OPRT expression was found to be a predictive factor of patient prognosis and occurrence of side-effects in CRC patients administered 5-FU-based chemotherapy. Following the detailed investigation of specimens resected surgically or by endoscopic biopsy, clinicians may be able to determine the most effective chemotherapeutic regimen. 
